Try our Advanced Search for more refined results

Expert Analysis

Takeaways From FDA's 1st Waiver Decision

Law360, New York (March 8, 2013, 11:45 AM EST) -- On Feb. 22, 2013, the U.S. Food and Drug Administration approved two generic drugs with a risk evaluation and mitigation strategies (REMS) program that differed from the innovator company's existing REMS program. This decision appears to be the first time that the FDA has waived the requirement for a "single shared system" under Section 505-1 of the federal Food, Drug and Cosmetic Act (FDC Act), which was created by Section 901 of the Food and Drug Administration Amendments Act of 2007 (the FDAAA)....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!